Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Raymond James has reiterated a Strong Buy rating and $32.00 price target on ARS Pharmaceuticals Inc (NASDAQ:SPRY) following the company’s second-quarter 2025 earnings report. According to InvestingPro data, while the stock has declined over 10% in the past week, it has shown strong momentum with a 31% gain over the last six months. Analyst targets range from $25 to $40, suggesting significant upside potential.
The pharmaceutical company reported net sales of $12.8 million for its neffy product, with approximately 35,000 neffy 2-packs sold during the quarter. Management disclosed that neffy has achieved 93% commercial coverage, with 57% of coverage requiring no prior authorization. The company maintains a strong financial position with a current ratio of 6.17, indicating robust liquidity to support its growth initiatives.
ARS Pharmaceuticals has seen significant adoption among healthcare providers, with more than 9,700 HCPs now prescribing neffy, representing a 73% increase since April 2025. Additionally, 2,800 allergists have enrolled in the neffy Experience Program with 20,000 doses available for in-office use.
The company’s educational initiatives are also gaining traction, with more than 3,200 schools participating in the neffyinSchools program. Raymond James views these developments as positive tailwinds for the product’s early launch phase.
Raymond James believes the company’s new direct-to-consumer campaign and ALK co-promotion deal will be the biggest drivers of future growth, noting that weekly prescription growth has already begun accelerating in the third quarter as the peak epinephrine sales season approaches. While analysts expect some revenue decline this year, InvestingPro analysis reveals 10 additional key insights about SPRY’s growth prospects and financial health. Get the full analysis and detailed Fair Value estimate with an InvestingPro subscription.
In other recent news, ARS Pharmaceuticals reported its second-quarter 2025 earnings, highlighting a revenue of $15.7 million. This figure exceeded the forecasted $13.77 million by 14.16%, demonstrating a stronger-than-expected performance in this period. However, the company’s earnings per share (EPS) aligned with expectations, remaining at -$0.46. These recent developments reflect the company’s ability to surpass revenue projections while maintaining anticipated earnings levels. Despite the revenue beat, the stock experienced a slight premarket decline. Investors may find these financial results significant as they consider the company’s recent performance and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.